Pharmaceuticals New Zealand

New Zealand Insulin Biosimilars Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

New Zealand Insulin Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Type, Delivery, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $40.2 Mn Placeholder estimate
Estimate 2025 $45.9 Mn 1% of the global market
Projected 2034 $151.7 Mn 230.4% Adds $105.8 Mn over 9 forecast years
CAGR 2025–2034 14.2% Faster than 72% of 160 Pharmaceuticals markets here
Key players 6 +1
  • New Zealand is 1.04% of the global market.
  • In APAC, the largest is China at $324.4 Mn.
  • Fastest growing: India at 17% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$105.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Insulin Biosimilars Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $40.2 Mn — —
2025 (base) $45.9 Mn +$5.7 Mn —
2026 (forecast) $52.4 Mn +$6.5 Mn +14.2%
2027 (forecast) $59.9 Mn +$7.4 Mn +30.4%
2028 (forecast) $68.4 Mn +$8.5 Mn +48.9%
2029 (forecast) $78.1 Mn +$9.7 Mn +70.1%
2030 (forecast) $89.2 Mn +$11.1 Mn +94.2%
2031 (forecast) $101.8 Mn +$12.7 Mn +121.8%
2032 (forecast) $116.3 Mn +$14.5 Mn +153.3%
2033 (forecast) $132.8 Mn +$16.5 Mn +189.3%
2034 (forecast) $151.7 Mn +$18.9 Mn +230.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand Insulin Biosimilars Market Analysis at a glance
Market size, 2025$45.9 Mn placeholder estimate
Forecast, 2034$151.7 Mn placeholder estimate
Growth (CAGR), 2025–203414.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, delivery and end user (see all)
Key playersBiocon, Viatris, Sanofi, Eli Lilly and Company, Gan & Lee Pharmaceuticals and 1 more (see all)
Regulator in New ZealandMedsafeSource: Medsafe. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand Insulin Biosimilars Market Analysis Executive Summary

Insulin biosimilars are lower-cost versions of branded insulins that work the same way, improving access to diabetes treatment.

Key segments of the insulin Biosimilars market include type (Long-Acting, Rapid-Acting and Premixed) and delivery (Vials, Pens and Cartridges).

Bar chart: New Zealand Insulin Biosimilars market size, 2024–2034, placeholder estimates. $40.2 Mn in 2024, $45.9 Mn in 2025 and $151.7 Mn in 2034, 14.2% CAGR.
New Zealand Insulin Biosimilars market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand Insulin Biosimilars Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the insulin Biosimilars market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the insulin Biosimilars market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the insulin Biosimilars market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Insulin Biosimilars Market in New Zealand

The insulin Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Insulin Biosimilars Market in New Zealand

Insulin Biosimilars in New Zealand: rules, payment and health figures

Medsafe, part of the Ministry of Health, approves medicines before they can be sold.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2] Diabetes (adults): 9.0% of adults in 2022, the latest WHO figure for New Zealand.⁠[3]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for insulin Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Insulin Biosimilars right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Insulin Biosimilars in context

New Zealand compared

  • Diabetes (adults, WHO): 9.0% of adults (2022). World: 14.1% of adults (2022). 13th highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 15 countries we cover in APAC.[2]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Insulin Biosimilars market in New Zealand?
Placeholder estimate: about $45.9 Mn in 2025, rising to about $151.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Insulin Biosimilars market in New Zealand growing?
Placeholder estimate: about 14.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Insulin Biosimilars market report cover?
The report splits the market by type (Long-Acting, Rapid-Acting, Premixed), delivery (Vials, Pens, Cartridges) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Insulin Biosimilars market?
Key players include Biocon, Viatris, Sanofi, Eli Lilly and Company, Gan & Lee Pharmaceuticals and Wockhardt Ltd..
What is driving the Insulin Biosimilars market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the insulin Biosimilars market.
Who regulates Insulin Biosimilars in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
What does WHO report for New Zealand?
Diabetes (adults): 9.0% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
How many people in New Zealand are 65 or older?
17.6% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.
How much research is published on Insulin Biosimilars?
PubMed lists 35 papers on Insulin Biosimilars added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in New Zealand

See all

Related on diabetes and biologics and biosimilars

See the topic